New combined microRNA and protein plasmatic biomarker panel for pancreatic cancer.
New combined microRNA and protein plasmatic biomarker panel for pancreatic cancer.
复制标题
DOI：
10.18632/oncotarget.12406
复制
发表时间：
2016-11-29
期刊：
影响因子：
--
通讯作者：
Ma J
中科院分区：
文献类型：
--
作者：
Yuan W;Tang W;Xie Y;Wang S;Chen Y;Qi J;Qiao Y;Ma J
缺乏诊断标记物导致手术机会的丧失，因为大多数患者是在晚期确诊的。胰腺癌(PC)被认为是一种5年生存率低于10%的致命性疾病。因此，迫切需要开发前列腺癌的诊断生物标志物来控制该病的死亡率。这是一项病例对照研究，包括来自健康对照组(HC)、良性胰腺疾病(BPD)患者、PC患者和其他胃肠道(GI)癌症患者的640份血浆样本。本研究对miR-20a、miR-21、miR-25、miR-155、miR-196a、miR-210、巨噬细胞抑制因子-1(MIC-1)和CA19-9 8个候选生物标志物进行了评价，建立了两个诊断指标。PC患者血浆6种miRNAs和MIC-1、CA19-9水平均高于正常对照组(P<；0.001)。其中miR-20a、miR-21、miR-25、MIC-1和CA19-9可将PC患者与其他胃肠道肿瘤或BPD患者区分开来。通过多因素Logistic回归分析，我们建立了两个诊断PC的特异性指标(指标1包含miR-21、MIC-1和CA19-9；指标2包含miR-25、MIC-1和CA19-9)。在260例HC、168例PC、132例其他GI癌和80例BPD患者的随机设置中，这两项指标不仅对PC具有更高的敏感性，而且比CA19-9和单个生物标志物对区分PC与其他GI癌的特异度更高。这些结果表明，与使用单一标记物相比，将生物标记物组合为一组可以提高诊断价值。如本研究所示，这类面板可以为PC的诊断提供新的血浆生物标志物。
Lack of diagnostic makers results in loss of operation opportunity in that most patients are diagnosed at the late stage. Pancreatic cancer (PC) has been regarded as a fatal disease with a 5-year survival rate below 10%. Therefore, the development of diagnostic biomarkers for PC is in urgent need to control the mortality of the disease. This is a case-control study including 640 plasma samples from healthy controls (HC), patients with benign pancreatic diseases (BPD), patients with PC; and patients with other gastrointestinal (GI) cancers. Eight biomarker candidates, including miR-20a, miR-21, miR-25, miR-155, miR-196a, miR-210, Macrophage Inhibitory Cytokine-1(MIC-1) and CA19-9, were evaluated to establish two diagnostic indexes in this study. The plasma level of the six miRNAs and MIC-1, CA19-9 were elevated in PC patients compared with those of healthy controls (P<0.001). Among them, miR-20a, miR-21, miR-25, MIC-1 and CA19-9 could distinguish PC patients from those with other GI cancers or BPD. With multivariable logistic regression, we established two specific indexes for diagnosis of PC(Index1 contains miR-21, MIC-1 and CA19-9; Index2 contains miR-25, MIC-1 and CA19-9). In a randomized setting of 260 HC, 168 PC, 132 other GI cancers and 80 BPD patients, both indexes performed not only better sensitivity for PC but also better specificity to distinguish PC from other GI cancers than CA19-9 and individual biomarkers. These results indicated that combination of biomarkers as a panel could improve diagnostic values compared with using a single marker. Such panels as illustrated in this study could provide novel plasmatic biomarker for PC diagnosis.